Ann Marie Ruhe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ann Marie Ruhe has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Achsah Philip
Department of Information Solutions, Medical University of South Carolina, Charleston, SC, United States
1 shared publication - Amy Hebbard
Coordinator for Psychiatric Pharmacy Services - MUSC Health, Charleston, South Carolina; Affiliate Assistant Professor, Medical University of South Carolina College of Pharmacy, Charleston, South Carolina
1 shared publication - Clinton A. Ross
Pharmacy Manager, Medical University of South Carolina, Charleston, South Carolina
1 shared publication - David Procaccini
Department of Pharmacy, Nemours Children's Hospital, Wilmington, Delaware, USA
1 shared publication - Genevieve Luehrs Hayes
Clinical Specialist, Outcomes Management, MUSC Medical Center/South Carolina College of Pharmacy Residency Program, Medical University of South Carolina (MUSC), Charleston, South Carolina
1 shared publication Imran Qureshi
Department of Pharmacy, The Johns Hopkins Hospital, 600 N Wolfe Street, Baltimore, MD 21287, USA
1 shared publication
Latest Publications
- 27 September 2024
- Published by Elsevier in Child and Adolescent Psychiatric Clinics of North America
- Vol. 34 (1) , 1-12
The Role of the Pharmacist on an Inpatient Child and Adolescent Psychiatry Unit
- 27 September 2024
- Published by Elsevier in Child and Adolescent Psychiatric Clinics of North America
- Vol. 34 (1) , 1-12
The Role of the Pharmacist on an Inpatient Child and Adolescent Psychiatry Unit
- Open Access
- 1 March 2019
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 9 (2) , 105-109
Evaluation and optimization of take-home naloxone in an academic medical center
With the United States in the midst of an opioid overdose epidemic, efforts to reduce overdose deaths have increased. Expanding access to the opioid antagonist naloxone can combat the epidemic. A pilot project in a psychiatric hospital resulted in the development of a screening tool in the electronic medical record (EMR) to help pharmacists identify adult inpatients at high risk of opioid overdose. Pharmacists can facilitate these patients being discharged with take-home naloxone. The purpose of this project was to optimize the screening tool for nonpsychiatric adult inpatient areas. Prior to implementation, a team of pharmacists familiar with the screening tool and take-home naloxone met with stakeholders to assess need for modification of the tool, determine barriers to implementation, and provide insight into the new service. In addition to expanding the tool into nonpsychiatric areas, a morphine-equivalents calculator was developed to identify patients receiving at least 100 mg of morphine equivalents per day to capture an additional at-risk population. Four short educational videos were developed to provide training to pharmacists. Initial performance of the screening tool was evaluated in general medicine patients over a 5-day period. Out of 44 admissions, 8 (18.2%) screened positive. The majority of those patients (5/8, 62.5%) screened positive for morphine equivalents greater than 100 mg. Anecdotally, the educational videos have been well received by pharmacy staff. Opioid overdose risk factors can be applied to nonpsychiatric inpatients for screening purposes in the EMR. Educational videos can be used to disseminate information to pharmacists on take-home naloxone and opioid overdose.
- 1 March 2019
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 9 (2) , 105-109
Open AccessEvaluation and optimization of take-home naloxone in an academic medical center
With the United States in the midst of an opioid overdose epidemic, efforts to reduce overdose deaths have increased. Expanding access to the opioid antagonist naloxone can combat the epidemic. A pilot project in a psychiatric hospital resulted in the development of a screening tool in the electronic medical record (EMR) to help pharmacists identify adult inpatients at high risk of opioid overdose. Pharmacists can facilitate these patients being discharged with take-home naloxone. The purpose of this project was to optimize the screening tool for nonpsychiatric adult inpatient areas. Prior to implementation, a team of pharmacists familiar with the screening tool and take-home naloxone met with stakeholders to assess need for modification of the tool, determine barriers to implementation, and provide insight into the new service. In addition to expanding the tool into nonpsychiatric areas, a morphine-equivalents calculator was developed to identify patients receiving at least 100 mg of morphine equivalents per day to capture an additional at-risk population. Four short educational videos were developed to provide training to pharmacists. Initial performance of the screening tool was evaluated in general medicine patients over a 5-day period. Out of 44 admissions, 8 (18.2%) screened positive. The majority of those patients (5/8, 62.5%) screened positive for morphine equivalents greater than 100 mg. Anecdotally, the educational videos have been well received by pharmacy staff. Opioid overdose risk factors can be applied to nonpsychiatric inpatients for screening purposes in the EMR. Educational videos can be used to disseminate information to pharmacists on take-home naloxone and opioid overdose.
- Open Access
- 1 November 2018
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 8 (6) , 313-316
Clozapine-induced myocarditis in an adolescent male with DiGeorge Syndrome
DiGeorge Syndrome (22q11.2 deletion syndrome) is a chromosomal disorder associated with both congenital heart malformations and schizophrenia, which is often treatment-resistant and may warrant treatment with clozapine. Clozapine-induced myocarditis (CIM) is a rare complication of clozapine therapy, with a reported incidence ranging from 0.015% to 3%. Fulminant CIM has a nonspecific presentation in both adult and pediatric populations and a mortality rate approaching 50%. Few cases of pediatric CIM have been documented in the literature. This report highlights a case of CIM in an adolescent male with DiGeorge Syndrome whose clinical course was characterized by a subtle, nonspecific presentation and resolution with supportive care.
- 1 November 2018
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 8 (6) , 313-316
Open AccessClozapine-induced myocarditis in an adolescent male with DiGeorge Syndrome
DiGeorge Syndrome (22q11.2 deletion syndrome) is a chromosomal disorder associated with both congenital heart malformations and schizophrenia, which is often treatment-resistant and may warrant treatment with clozapine. Clozapine-induced myocarditis (CIM) is a rare complication of clozapine therapy, with a reported incidence ranging from 0.015% to 3%. Fulminant CIM has a nonspecific presentation in both adult and pediatric populations and a mortality rate approaching 50%. Few cases of pediatric CIM have been documented in the literature. This report highlights a case of CIM in an adolescent male with DiGeorge Syndrome whose clinical course was characterized by a subtle, nonspecific presentation and resolution with supportive care.
- Open Access
- 1 March 2018
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 8 (2) , 68-72
Assessment of venous thromboembolism risk and initiation of appropriate prophylaxis in psychiatric patients
Introduction: Venous thromboembolism (VTE) prophylaxis is not included among the measures for the Inpatient Psychiatric Facilities Quality Reporting Program. Evidence suggests that antipsychotic agents may be an independent risk factor for the development of VTE; therefore, development of a VTE risk stratification tool would improve the quality and safety of care for the psychiatric inpatient population. This study aims to develop clinically relevant criteria to assess VTE risk upon admission to an inpatient psychiatric hospital. Methods: This retrospective, single-center cohort study enrolled patients in 2 cohorts from an inpatient psychiatric hospital. Patients in cohort I with new-onset VTE diagnosis during admission were identified through international classification of diseases 9 and 10 coding. Cohort II consisted of a random sample of 100 patients in a 3-month period. The percentage meeting criteria for prophylaxis in each cohort was assessed utilizing both the Padua Prediction Score and a modified score. Results: In cohorts I and II, 66.7% and 14% of patients, respectively, met criteria for VTE prophylaxis utilizing the modified Padua Prediction Score. One patient received VTE prophylaxis in each cohort, and the median time to VTE diagnosis in cohort I was 42 days. In cohort I, the rate of VTE was 0.08% based on estimated discharges in the 26-month period. This is less than the annual rate of 1% to 2.4% for nursing homes or postacute rehabilitation facilities. Discussion: We recommend the implementation of clinical decision support to prompt individualized reassessment of VTE risk when length of stay exceeds 30 days.
- 1 March 2018
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 8 (2) , 68-72
Open AccessAssessment of venous thromboembolism risk and initiation of appropriate prophylaxis in psychiatric patients
Introduction: Venous thromboembolism (VTE) prophylaxis is not included among the measures for the Inpatient Psychiatric Facilities Quality Reporting Program. Evidence suggests that antipsychotic agents may be an independent risk factor for the development of VTE; therefore, development of a VTE risk stratification tool would improve the quality and safety of care for the psychiatric inpatient population. This study aims to develop clinically relevant criteria to assess VTE risk upon admission to an inpatient psychiatric hospital. Methods: This retrospective, single-center cohort study enrolled patients in 2 cohorts from an inpatient psychiatric hospital. Patients in cohort I with new-onset VTE diagnosis during admission were identified through international classification of diseases 9 and 10 coding. Cohort II consisted of a random sample of 100 patients in a 3-month period. The percentage meeting criteria for prophylaxis in each cohort was assessed utilizing both the Padua Prediction Score and a modified score. Results: In cohorts I and II, 66.7% and 14% of patients, respectively, met criteria for VTE prophylaxis utilizing the modified Padua Prediction Score. One patient received VTE prophylaxis in each cohort, and the median time to VTE diagnosis in cohort I was 42 days. In cohort I, the rate of VTE was 0.08% based on estimated discharges in the 26-month period. This is less than the annual rate of 1% to 2.4% for nursing homes or postacute rehabilitation facilities. Discussion: We recommend the implementation of clinical decision support to prompt individualized reassessment of VTE risk when length of stay exceeds 30 days.